for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lannett Company, Inc.

LCI.N

Latest Trade

8.86USD

Change

-0.32(-3.49%)

Volume

280,196

Today's Range

8.77

 - 

9.19

52 Week Range

4.34

 - 

15.37

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Lannett Announces Positive Results From Human Clinical Trial Of Biosimilar Insulin Glargine Versus U.S. Lantus

Dec 4 (Reuters) - Lannett Company Inc <LCI.N>::LANNETT ANNOUNCES POSITIVE RESULTS FROM HUMAN CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE VERSUS US LANTUS®.LANNETT COMPANY INC - STUDY ACHIEVES ALL PRIMARY ENDPOINTS.LANNETT COMPANY INC - COMPANY TO SET MEETING WITH FDA REGARDING PIVOTAL TRIAL DESIGN.LANNETT COMPANY INC - INSULIN GLARGINE WAS SAFE AND WELL TOLERATED.LANNETT COMPANY INC - NO SERIOUS ADVERSE EVENTS (SAES) OR SERIOUS ADVERSE DRUG REACTIONS RELATED TO DRUG WERE OBSERVED DURING STUDY.LANNETT COMPANY - EXPECT TO MEET WITH FDA IN COMING MONTHS TO PLAN NEXT STEPS FOR CLINICAL ADVANCEMENT OF LANTUS.

Lannett Company Inc Enters Into A Collaboration And License Agreement With HEC

Nov 26 (Reuters) - Lannett Company Inc <LCI.N>::LANNETT COMPANY INC - ENTERED INTO A COLLABORATION AND LICENSE AGREEMENT WITH HEC.LANNETT COMPANY INC - AGREEMENT REPLACES AGREEMENT IN PRINCIPAL PREVIOUSLY ENTERED INTO BETWEEN COMPANY AND HEC.LANNETT COMPANY INC - CO, HEC WILL SHARE RESPONSIBILITY FOR AND CONTROL OF DEVELOPING INSULIN GLARGINE PRODUCT IN U.S..LANNETT COMPANY INC - WILL PAY DEVELOPMENT COSTS FOR PRODUCT UP TO $32 MILLION.LANNETT - WILL SHARE ADDITIONAL PRODUCT DEVELOPMENT COSTS IN EXCESS OF $32 MILLION WITH HEC AT A 50/50 SPLIT FOR UP TO NEXT $13 MILLION.LANNETT COMPANY INC - HEC WILL HAVE SOLE RESPONSIBILITY FOR MANUFACTURING PRODUCT.

Lannett Posts Q1 Loss Per Share Of $0.32

Nov 6 (Reuters) - Lannett Company Inc <LCI.N>::LANNETT ANNOUNCES FISCAL 2020 FIRST-QUARTER FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.22.Q1 SALES $127.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $120.8 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.19 -- REFINITIV IBES DATA.Q1 LOSS PER SHARE $0.32.REITERATED ADJUSTED GUIDANCE FOR FISCAL YEAR 2020, EXCEPT FOR INTEREST AND OTHER.SEES FISCAL 2020 GAAP NET SALES $525 MILLION TO $545 MILLION.FY2020 REVENUE VIEW $535.8 MILLION -- REFINITIV IBES DATA.

Lannett Co Enters Into Distribution Agreement For Generic Advair Diskus

Oct 1 (Reuters) - Lannett Company Inc <LCI.N>::LANNETT ENTERS INTO DISTRIBUTION AGREEMENT FOR GENERIC ADVAIR DISKUS®.LANNETT COMPANY INC - WILL COMMENCE U.S. DISTRIBUTION OF GENERIC ADVAIR DISKUS AFTER FDA APPROVAL.LANNETT COMPANY - WORKING WITH RESPIRENT TEAM TO COMPLETE PRODUCT FILING, WHICH CO EXPECTS TO SUBMIT TO FDA IN SECOND HALF OF OUR CURRENT FISCAL YEAR.LANNETT - TO MAKE UPFRONT PAYMENT, FUTURE MILESTONE PAYMENTS & RECEIVE PORTION OF NET PROFITS ONCE IT COMMENCES DISTRIBUTION OF PRODUCT.LANNETT COMPANY - TERM OF AGREEMENT IS 10 YEARS, WHICH BEGINS UPON COMMENCEMENT OF DISTRIBUTION OF PRODUCT.LANNETT COMPANY - OTHER TERMS WERE NOT DISCLOSED.

Lannett Announces Pricing Of $75 Million Of Convertible Senior Notes Due 2026

Sept 25 (Reuters) - Lannett Company Inc <LCI.N>::LANNETT ANNOUNCES PRICING OF $75 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2026.LANNETT COMPANY INC - NOTES WILL BEAR INTEREST AT A RATE OF 4.50% PER YEAR.

Lannett Announces Offering Of $75 Million Of Convertible Senior Notes Due 2026

Sept 24 (Reuters) - Lannett Company Inc <LCI.N>::LANNETT ANNOUNCES OFFERING OF $75 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2026.LANNETT COMPANY - INTENDS TO GRANT INITIAL PURCHASER OF NOTES A 30-DAY OPTION TO PURCHASE UP TO ADDITIONAL $11.25 MILLION AMOUNT OF NOTES.LANNETT COMPANY INC - NOTES WILL MATURE ON OCTOBER 1, 2026.LANNETT COMPANY - REGARDING NOTES OFFERING, EXPECTS TO ENTER INTO CAPPED CALL TRANSACTION WITH AFFILIATE OF INITIAL PURCHASER OF NOTES.LANNETT COMPANY INC - EXPECTS TO USE A PORTION OF NET PROCEEDS FROM OFFERING TO PAY COST OF CAPPED CALL TRANSACTION.

Lannett Enters Into Distribution Agreement For Posaconazole Delayed-Release Tablets

Aug 28 (Reuters) - Lannett Company Inc <LCI.N>::LANNETT ENTERS INTO DISTRIBUTION AGREEMENT FOR POSACONAZOLE DELAYED-RELEASE TABLETS; LAUNCH TO COMMENCE SHORTLY.LANNETT COMPANY INC - ENTERED INTO AN AGREEMENT WITH SINOTHERAPEUTICS.LANNETT COMPANY INC - EXPECTS TO COMMENCE SHIPPING PRODUCT SHORTLY..LANNETT COMPANY INC - DEAL WITH SINOTHERAPEUTICS TO BE EXCLUSIVE U.S. DISTRIBUTOR OF POSACONAZOLE DELAYED-RELEASE TABLETS 100MG.LANNETT COMPANY INC - OTHER TERMS WERE NOT DISCLOSED.LANNETT COMPANY INC - UNDER AGREEMENT, LANNETT WILL MAKE MILESTONE PAYMENTS BASED ON MARKET DYNAMICS AND PERFORMANCE.

Lannett Comments On Agreement With Sinotherapeutics

Aug 27 (Reuters) - Lannett Company Inc <LCI.N>::LANNETT - COMMENTS ON AGREEMENT WITH SINOTHERAPEUTICS WHERE CO IS EXCLUSIVE DISTRIBUTOR OF POSACONAZOLE DELAYED-RELEASE TABLETS 100MG.LANNETT COMPANY INC - ON AUGUST 21, 2019, SINOTHERAPEUTICS RECEIVED FINAL APPROVAL FROM FDA FROM ANDA FOR POSACONAZOLE DELAYED-RELEASE TABLETS 100MG.LANNETT COMPANY INC - COMPANY HAS DETERMINED THAT DISTRIBUTION AGREEMENT WILL BE A MATERIAL DEFINITIVE AGREEMENT..LANNETT COMPANY INC - COMPANY WILL BE REQUIRED TO PAY SINOTHERAPEUTICS A PORTION OF NET PROFITS COMPANY RECEIVES FROM SALE OF PRODUCTS.

Lannett Company Posts Q4 Adjusted Earnings Per Share of $0.37

Aug 27 (Reuters) - Lannett Company Inc <LCI.N>::LANNETT ANNOUNCES FISCAL 2019 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS; ISSUES GUIDANCE FOR FISCAL 2020.Q4 ADJUSTED EARNINGS PER SHARE $0.37.Q4 LOSS PER SHARE $0.20.Q4 SALES $133.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $121.7 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.21 -- REFINITIV IBES DATA.LANNETT COMPANY - SEES 2020 ADJUSTED EBITDA $145 MILLION TO $160 MILLION.SEES FISCAL 2020 NET SALES $525 MILLION TO $545 MILLION.SEES FISCAL 2020 CAPITAL EXPENDITURES $20 MILLION TO $25 MILLION.SEES FISCAL 2020 RESTRUCTURING EXPENSE $2 MILLION TO $4 MILLION.FY2020 REVENUE VIEW $506.0 MILLION -- REFINITIV IBES DATA.

Lannett Co Enters Into Distribution Agreement For Levothyroxine

July 8 (Reuters) - Lannett Company Inc <LCI.N>::LANNETT ENTERS INTO DISTRIBUTION AGREEMENT FOR LEVOTHYROXINE.LANNETT COMPANY INC - TERM OF AGREEMENT IS 10 YEARS, WHICH BEGINS UPON COMMENCEMENT OF DISTRIBUTION.LANNETT COMPANY INC - OTHER TERMS WERE NOT DISCLOSED..LANNETT COMPANY INC - LANNETT WILL COMMENCE U.S. DISTRIBUTION OF PRODUCT NO LATER THAN AUGUST 1, 2022.LANNETT COMPANY INC - LANNETT WILL MAKE AN UPFRONT PAYMENT OF $20 MILLION WITHIN NEXT FIVE BUSINESS DAYS.LANNETT - ENTERED INTO FUTURE EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENT FOR APPROVED LEVOTHYROXINE SODIUM TABLETS USP OF CEDIPROF.LANNETT COMPANY - WILL RECEIVE A PORTION OF NET PROFITS ONCE IT COMMENCES DISTRIBUTION OF LEVOTHYROXINE SODIUM TABLETS USP.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up